Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/3/16 → 3/6/19 |
Funding
- Edge Therapeutics Incorporated: $259,791.00
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to SOC Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage
- Hatton, Kevin (PI)
- Fischer, Brian (CoI)
- Fraser, Justin (CoI)